Drugs / PYX-201
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05720117 | Mar 2023 → Apr 2027 expected | neoplasm | Pyxis Oncology, Inc | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06795412 | Apr 2025 → Dec 2027 expected | cancer | Pyxis Oncology, Inc | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PYX-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05720117 ↗ |
| Modality | Other / unclassified | “Antibody-Drug Conjugate” NCT05720117 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion.” NCT06795412 ↗ |